Table 5.
Association between OM and BMI and covariates
| Variable | HR | 95% CI | p-value | |
|---|---|---|---|---|
| BMI, continuous(kg/m2) | 1.05 | 1.02–1.08 | 0.004 | |
| Gleason Score | ||||
| 7 vs 6 | 1.19 | 0.78–1.80 | 0.417 | |
| 8–10 vs 6 | 1.18 | 0.65–2.14 | 0.595 | |
| T-stage | ||||
| T2 vs T1c | 1.21 | 0.82–1.78 | 0.327 | |
| T3/4 vs T1c | 1.44 | 0.75–2.76 | 0.269 | |
| Log iPSA(ng/mL) | 1.35 | 1.06–1.73 | 0.016 | |
| Age(years) | 1.08 | 1.05–1.11 | <0.001 | |
| ADT Use(yes vs no) | 1.04 | 0.66–1.65 | 0.858 | |
| Comorbidities(yes vs no) | ||||
| Diabetes | 1.54 | 1.03–2.28 | 0.034 | |
| Hypertension | 1.48 | 1.01–2.17 | 0.045 | |
| Heart Disease | 1.19 | 0.81–1.76 | 0.373 | |
DM, distant metastasis; CSM, cause-specific mortality; OM, overall mortality; BMI, body mass index; HR, hazard ratio; ADT, androgen deprivation therapy; iPSA, pre-treatment prostate specific antigen.